Review
Nature Reviews Drug Discovery 1, 797-807 (October 2002) | doi:10.1038/nrd914
Toll-like receptors as potential therapeutic targets for multiple diseases
Claudia Zuany-Amorim1, John Hastewell1 & Christoph Walker1 About the authors
Abstract
The family of Toll-like receptors (TLRs) is receiving considerable attention as potential regulators and controllers of the immune response through their ability to recognize pathogen-associated molecular patterns. The discovery that endogenous ligands, as well as microbial components, are recognized by TLRs, and that small-molecular-mass synthetic compounds activate TLRs, raised interest in these receptors as potential targets for the development of new therapies for multiple diseases. In this review, we discuss the current and future use of TLR agonists or antagonists in chronic inflammatory diseases and highlight potential problems that are associated with such approaches.
- View At a Glance
Author affiliations
- Novartis Horsham Research Centre, Novartis Pharmaceutical Ltd, Wimblehurst Road, Horsham, West Sussex RH12 5AB, UK.
Correspondence to: Christoph Walker1 Email: christoph.walker@pharma.novartis.com
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE NEWS AND VIEWS RESEARCH |
